315 related articles for article (PubMed ID: 24518562)
1. Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data.
Trkulja V; Lalić Z; Nađ-Škegro S; Lebo A; Granić P; Lovrić M; Pasini J; Božina N
Ther Drug Monit; 2014 Aug; 36(4):456-64. PubMed ID: 24518562
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
[TBL] [Abstract][Full Text] [Related]
4. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
[TBL] [Abstract][Full Text] [Related]
6. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
Lam H; Jeffery J; Sitar DS; Aoki FY
Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
[TBL] [Abstract][Full Text] [Related]
7. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
[TBL] [Abstract][Full Text] [Related]
8. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
[TBL] [Abstract][Full Text] [Related]
9. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
Aw MM; Brown NW; Itsuka T; Gonde CE; Adams JE; Heaton ND; Tredger JM; Mieli-Vergani G; Dhawan A
Liver Transpl; 2003 Apr; 9(4):383-8. PubMed ID: 12682891
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of limited sampling strategies for tacrolimus and mycophenolate in steroid-free renal transplant regimens.
Poulin E; Greanya ED; Partovi N; Shapiro RJ; Al-Khatib M; Ensom MH
Ther Drug Monit; 2011 Feb; 33(1):50-5. PubMed ID: 21157401
[TBL] [Abstract][Full Text] [Related]
12. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
Mardigyan V; Giannetti N; Cecere R; Besner JG; Cantarovich M
J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
[TBL] [Abstract][Full Text] [Related]
13. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.
Lloberas N; Torras J; Cruzado JM; Andreu F; Oppenheimer F; Sánchez-Plumed J; Gentil MÁ; Brunet M; Ekberg H; Grinyó JM;
Nephrol Dial Transplant; 2011 Nov; 26(11):3784-93. PubMed ID: 21427078
[TBL] [Abstract][Full Text] [Related]
14. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients.
Mandla R; Midtvedt K; Line PD; Hartmann A; Bergan S
Transpl Int; 2006 Jan; 19(1):44-53. PubMed ID: 16359376
[TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions.
Božina N; Lalić Z; Nađ-Škegro S; Borić-Bilušić A; Božina T; Kaštelan Ž; Trkulja V
Eur J Clin Pharmacol; 2017 Sep; 73(9):1129-1140. PubMed ID: 28624888
[TBL] [Abstract][Full Text] [Related]
17. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
van Gelder T; Silva HT; de Fijter H; Budde K; Kuypers D; Mamelok RD; Armstrong VW; Oellerich M
Ther Drug Monit; 2011 Apr; 33(2):155-64. PubMed ID: 21383657
[TBL] [Abstract][Full Text] [Related]
18. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
[TBL] [Abstract][Full Text] [Related]
19. Influence of renal graft function on mycophenolic acid pharmacokinetics during the early period after kidney transplant.
Mohammadpur AH; Nazemian F; Abtahi B; Naghibi M
Exp Clin Transplant; 2008 Dec; 6(4):276-81. PubMed ID: 19338489
[TBL] [Abstract][Full Text] [Related]
20. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.
Tredger JM; Brown NW; Adams J; Gonde CE; Dhawan A; Rela M; Heaton N
Liver Transpl; 2004 Apr; 10(4):492-502. PubMed ID: 15048791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
